Core Viewpoint - Junshi Bioscience has announced adjustments to certain sub-projects and funding amounts related to its fundraising initiatives, maintaining the total amount of raised funds unchanged [1][3]. Fundraising and Project Adjustments - The company held board and supervisory meetings on May 29, 2025, to approve changes to the "Innovative Drug R&D Project" under the 2022 fundraising efforts, specifically adjusting clinical trial sub-projects and their funding amounts [1]. - New sub-projects added include "JS207 domestic and international R&D," "JS107 domestic and international R&D," "JS125 domestic and international R&D," "JT002 domestic and international R&D," "JS203 domestic and international R&D," and "JS015 domestic and international R&D," with funding sourced from reduced amounts in other sub-projects [2]. Strategic Rationale - The adjustments are based on the company's development strategy and product R&D progress, aimed at improving the efficiency of fund utilization and optimizing resource allocation, thereby supporting long-term development [3]. - The changes will not adversely affect the company's normal operations and align with the long-term interests of all shareholders [3]. Fundraising Details - In 2022, Junshi Bioscience raised a total of RMB 3.7765 billion by issuing 70 million A-shares at a price of RMB 53.95 per share, with a net amount of RMB 3.7448 billion after deducting issuance costs [4]. - The funds were deposited into a special account for fundraising and were verified by a certified public accountant [4]. Company Performance - Since its listing on July 15, 2020, Junshi Bioscience has raised a total of RMB 8.613 billion through two fundraising rounds [7]. - The company reported a net profit attributable to shareholders of -2.35 billion in Q1 2025, an improvement from -2.83 billion in the same period last year, with a revenue of 5.01 billion, reflecting a year-on-year growth of 31.46% [7][8].

Group 1 - The company announced adjustments to the fundraising amounts for certain clinical trial sub-projects within its "Innovative Drug R&D Project" while keeping the total fundraising amount unchanged [1][2] - New sub-projects such as "JS207 domestic and overseas R&D," "JS107 domestic and overseas R&D," and "JS125 domestic and overseas R&D" have been added, while funding for several other drug developments has been reduced [1] - JS207 is a recombinant humanized anti-PD-1 and VEGF bispecific antibody developed by the company, primarily for the treatment of advanced malignancies, currently in Phase II clinical trials [1] Group 2 - The adjustments in fundraising project sub-items and amounts are based on the company's development strategy and product R&D progress, aimed at improving fundraising efficiency and optimizing resource allocation [2] - The changes are expected to provide financial support for the company's product development and contribute to its long-term growth [2]